CRISPR-TB South Africa distributor ILEX Expands Access to Advanced TB Blood Test Across Africa

IntelliGenome has appointed ILEX South Africa as the exclusive CRISPR-TB South Africa distributor, introducing the blood based TB test to address persistent gaps in tuberculosis diagnosis. This blood based TB test detects active Mycobacterium tuberculosis complex infections by identifying circulating cell-free DNA in serum or plasma, bypassing the need for sputum samples that often prove difficult to obtain from patients with HIV co-infection or young children. The approach supports South Africa’s national TB recovery plans by accelerating case detection and expanding access to molecular testing in high-burden communities.

CRISPR-Enhanced Detection Method

The assay relies on CRISPR-based cleavage to isolate low-abundance Mycobacterium tuberculosis complex cell-free DNA, producing a signal that reflects current bacterial replication rather than past exposure. Both laboratory and near-patient formats are advancing to suit different resource settings. Prior regulatory achievements, including U.S. FDA Breakthrough Device Designation and CE-IVDD certification, provide the technical foundation for rollout.

Addressing South Africa’s TB Burden

South Africa records hundreds of thousands of tuberculosis cases each year, with roughly half involving HIV co-infection and a notable portion remaining undiagnosed. The distributor’s established presence across sixteen additional African nations supplies the regulatory, technical, and scientific support needed for introduction. Similar agreements in Latin America and Asia reflect a broader strategy of regional partnerships that leverage local expertise to speed adoption of non-sputum molecular methods.

Ad

Strategic Value of Blood Based TB Test Expansion

For health economics and outcomes research, the blood based TB test can reduce dependence on resource-intensive sputum procedures while shortening the time to confirmed diagnosis. Market-access planning can align with existing national TB frameworks to support reimbursement and accelerate case-finding goals. Regional expansion through a single distributor may lower per-country entry costs and generate real-world performance data across varied patient populations. This initiative builds on the company’s South Africa expansion to strengthen diagnostic capacity continent-wide.